Dataset Viewer
Auto-converted to Parquet Duplicate
document_content_chunk
stringlengths
265
9.83k
genereated_question
stringlengths
180
987
trace
listlengths
4
4
⌀
model
stringclasses
1 value
__index_level_0__
int64
0
43.6k
period for individual outcomes. Table 10: Information on the course of the study – RCT, direct comparison: luspatercept vs. placebo ![](https://www.iqwig.de/download/images/120ef2c008729b2478d345077faec84b1f28abc907de52f9cda3f2db131660d5.jpg) AE: adverse event; max: maximum; min: minimum; N: number of randomized pat...
In a clinical trial assessing a novel drug for anemia, adverse events were monitored up to 9 weeks post-last dose, while quality-of-life measures were collected only during blinded treatment. What methodological implications arise from this differential observation period for outcome validity? How might this design inf...
[ { "content": "Please summarize the following context:\n\nperiod for individual outcomes.\n\nTable 10: Information on the course of the study – RCT, direct comparison: luspatercept vs. placebo\n\n![](https://www.iqwig.de/download/images/120ef2c008729b2478d345077faec84b1f28abc907de52f9cda3f2db131660d5.jpg)\n\nAE:...
Qwen/Qwen3-235B-A22B
0
The company did not provide any further information on the transferability of the study results to the German health care context. # I 4 Results on added benefit # I 4.1 Outcomes included The following patient-relevant outcomes were to be included in the assessment: Mortality  All-cause mortality  Morbidity  Tr...
In a clinical trial using the TranQoL questionnaire to assess health-related quality of life, researchers observed a statistically significant improvement in the 'physical health' domain but not in 'emotional health' or 'sexual activity.' Given the TranQoL's structure (36 items, 5 domains, 75% completion threshold), wh...
[ { "content": "Please summarize the following context:\n\nThe company did not provide any further information on the transferability of the study results to the German health care context.\n\n# I 4 Results on added benefit\n\n# I 4.1 Outcomes included\n\nThe following patient-relevant outcomes were to be include...
Qwen/Qwen3-235B-A22B
1
), emotional health (questions 11 to 24), sexual activity (question 25), family situation (questions 26 to 30) as well as school and work (questions 31 to 36). The reference period of the questionnaire is one week. There are 5 answer categories per question, which are specified by the patient: never, almost never, some...
In a randomized controlled trial, 19% of participants in the intervention group and 17% in the control group had missing data for a key PRO measure. The researchers conducted sensitivity analyses by imputing missing values as non-responders. How does this approach affect the interpretation of the study's results, and w...
[ { "content": "Please summarize the following context:\n\n), emotional health (questions 11 to 24), sexual activity (question 25), family situation (questions 26 to 30) as well as school and work (questions 31 to 36). The reference period of the questionnaire is one week. There are 5 answer categories per questi...
Qwen/Qwen3-235B-A22B
2
on all outcomes was rated as low. For the outcomes on healthrelated quality of life (SF-36v2, TranQoL), there was a high proportion of patients who were not considered in the analysis (between $17%$ and $19%$ ). However, the company presented supplementary sensitivity analyses in the dossier, in which missing values we...
A study reports no statistically significant difference in adverse event (AE) discontinuation rates between a treatment and control group. However, the study acknowledges that patients who discontinued for other reasons may have experienced AEs that could have led to discontinuation. How might this competing event bias...
[ { "content": "Please summarize the following context:\n\non all outcomes was rated as low. For the outcomes on healthrelated quality of life (SF-36v2, TranQoL), there was a high proportion of patients who were not considered in the analysis (between $17%$ and $19%$ ). However, the company presented supplementar...
Qwen/Qwen3-235B-A22B
3
did not require transfusions for $\\geq24$ weeks. Overall, this resulted in no hint of an added benefit of luspatercept in comparison with the ACT for the outcome “transfusion avoidance”; an added benefit is therefore not proven. # Health-related quality of life # SF-36v2 and TranQoL There was no statistically sign...
In a subgroup analysis of a hematology treatment trial, researchers identify a statistically significant interaction between treatment efficacy and patient age (≤32 vs. >32 years). However, one subgroup has only 8 patients with the outcome of interest. What methodological concerns might this raise, and how should clini...
[ { "content": "Please summarize the following context:\n\ndid not require transfusions for $\\\\geq24$ weeks.\n\nOverall, this resulted in no hint of an added benefit of luspatercept in comparison with the ACT for the outcome “transfusion avoidance”; an added benefit is therefore not proven.\n\n# Health-related ...
Qwen/Qwen3-235B-A22B
4
})$ previous splenectomy (yes vs. no) Interaction tests are conducted when at least 10 patients per subgroup are included in the analysis. Moreover, for binary data, there had to be at least 10 events in at least 1 subgroup. Presented are only the results with an effect modification with a statistically significant ...
In a clinical study, a drug demonstrates a 18% vs. 1% reduction in transfusion burden over 24 weeks in the intervention versus comparator group. However, subgroup analyses for all-cause mortality and quality-of-life metrics show no significant differences. What factors might explain the discrepancy between the primary ...
[ { "content": "Please summarize the following context:\n\n})$\n\nprevious splenectomy (yes vs. no)\n\nInteraction tests are conducted when at least 10 patients per subgroup are included in the analysis. Moreover, for binary data, there had to be at least 10 events in at least 1 subgroup.\n\nPresented are only th...
Qwen/Qwen3-235B-A22B
5
even if in the BELIEVE study only individual patients were able to achieve longerlasting complete transfusion avoidance. For example, $18%$ of patients in the intervention vs. $1%$ in the comparator arm achieved a halving of their transfusion burden over $\\geq24$ weeks. Patients in the intervention arm achieved an ave...
Two independent healthcare assessment agencies reach conflicting conclusions regarding the efficacy of a novel treatment for transfusion-dependent anemia. One agency cites non-quantifiable added benefit, while the other identifies no proven advantage. Evaluate the methodological differences in their approaches that cou...
[ { "content": "Please summarize the following context:\n\neven if in the BELIEVE study only individual patients were able to achieve longerlasting complete transfusion avoidance. For example, $18%$ of patients in the intervention vs. $1%$ in the comparator arm achieved a halving of their transfusion burden over ...
Qwen/Qwen3-235B-A22B
6
Luspatercept (ACE-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta (β)-Thalassemia; The "BELIEVE" Trial; study ACE-536-B-THAL-001; Health-Related Quality Of Life Report \[unpublished\]. 2019. 06. Celgene. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Stud...
A clinical trial comparing a novel drug to placebo in transfusion-dependent thalassemia reported a 44% reduction in red blood cell transfusion needs. However, post-hoc analyses revealed variability in patient-reported outcomes. What factors might explain this discrepancy, and how would you reconcile these findings when...
[ { "content": "Please summarize the following context:\n\nLuspatercept (ACE-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta (β)-Thalassemia; The \"BELIEVE\" Trial; study ACE-536-B-THAL-001; Health-Related Quality Of Life Report \\[unpublished\\]. 2019.\n\n06. Celgene. A ...
Qwen/Qwen3-235B-A22B
7
_V3 \[online\]. 2022 \[Accessed: 14.04.2023\]. URL: [https://www.awmf.org/uploads/tx\_szleitlinien/025-029l\_S2k\_Diagnostik-Therapie-dersekundaeren-Eisenueberladung-bei-Patienten-mit-angeborenen-Anaemien\_2022-03\_1.pdf](https://www.awmf.org/uploads/tx_szleitlinien/025-029l_S2k_Diagnostik-Therapie-dersekundaeren-Eisen...
A clinician is evaluating quality of life (QoL) in a 12-year-old child with transfusion-dependent thalassemia. The TranQol questionnaire is being considered for assessment. What specific advantages does a disease-specific QoL measure like TranQol offer over generic tools in this context, and how might its psychometric ...
[ { "content": "Please summarize the following context:\n\n_V3 \\[online\\]. 2022 \\[Accessed: 14.04.2023\\]. URL: [https://www.awmf.org/uploads/tx\\_szleitlinien/025-029l\\_S2k\\_Diagnostik-Therapie-dersekundaeren-Eisenueberladung-bei-Patienten-mit-angeborenen-Anaemien\\_2022-03\\_1.pdf](https://www.awmf.org/upl...
Qwen/Qwen3-235B-A22B
8
measure (the TranQol) in adults and children with thalassaemia major. Br J Haematol 2014; 164(3): 431-437. [https://dx.doi.org/10.1111/bjh.12631](https://dx.doi.org/10.1111/bjh.12631). 21. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dokumentation und Würdigung der Anhörung zum Entwurf der Al...
In a phase III oncology trial, a new therapy is associated with grade 3/4 adverse events (per CTCAE criteria) in 15% of patients. The control group has a 10% incidence of similar events. What factors should the trial's data monitoring committee evaluate to determine whether this difference represents a clinically meani...
[ { "content": "Please summarize the following context:\n\nmeasure (the TranQol) in adults and children with thalassaemia major. Br J Haematol 2014; 164(3): 431-437.\n\n [https://dx.doi.org/10.1111/bjh.12631](https://dx.doi.org/10.1111/bjh.12631).\n\n21. Institut für Qualität und Wirtschaftlichkeit im Gesundhe...
Qwen/Qwen3-235B-A22B
9
End of preview. Expand in Data Studio
README.md exists but content is empty.
Downloads last month
109